Clinical Trial Update: Administration of Donor T Cells With the Caspase-9 Suicide Gene [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating donor T cells engineered with a caspase-9 suicide gene to enable controlled safety in hematologic diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Epstein-barr Virus Infection
• Familial Hemophagocytic Lymphohistiocytosis
• Hemophagocytic Lymphohistiocytosis
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• Donor T cells with caspase-9 suicide gene (inducible caspase-9 suicide gene)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: ACTIVE_NOT_RECRUITING